Short Interest in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Drops By 26.1%

Lyell Immunopharma, Inc. (NASDAQ:LYEL) was the recipient of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 5,980,000 shares, a drop of 26.1% from the February 28th total of 8,090,000 shares. Currently, 4.8% of the company’s stock are sold short. Based on an average trading volume of 1,090,000 shares, the days-to-cover ratio is presently 5.5 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price target on shares of Lyell Immunopharma in a research report on Thursday, March 13th.

Insiders Place Their Bets

In other Lyell Immunopharma news, CEO Lynn Seely acquired 175,000 shares of Lyell Immunopharma stock in a transaction that occurred on Friday, March 14th. The stock was acquired at an average price of $0.61 per share, with a total value of $106,750.00. Following the purchase, the chief executive officer now owns 712,500 shares in the company, valued at approximately $434,625. This trade represents a 32.56 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard Klausner purchased 158,000 shares of the firm’s stock in a transaction dated Friday, March 14th. The shares were bought at an average price of $0.60 per share, with a total value of $94,800.00. Following the purchase, the director now owns 843,365 shares in the company, valued at $506,019. This represents a 23.05 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 733,000 shares of company stock worth $429,550. 25.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Lyell Immunopharma

Institutional investors and hedge funds have recently made changes to their positions in the company. Centiva Capital LP bought a new position in Lyell Immunopharma in the third quarter valued at approximately $31,000. Graham Capital Management L.P. bought a new position in shares of Lyell Immunopharma during the 4th quarter valued at about $33,000. RPO LLC acquired a new stake in shares of Lyell Immunopharma during the fourth quarter worth $42,000. Intech Investment Management LLC bought a new stake in shares of Lyell Immunopharma in the third quarter valued at about $52,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Lyell Immunopharma during the third quarter worth about $52,000. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Price Performance

Shares of LYEL traded down $0.05 during mid-day trading on Tuesday, reaching $0.48. The company had a trading volume of 650,382 shares, compared to its average volume of 1,058,144. The company’s 50-day moving average is $0.61 and its 200-day moving average is $0.85. Lyell Immunopharma has a twelve month low of $0.48 and a twelve month high of $3.15. The company has a market capitalization of $142.98 million, a P/E ratio of -0.61 and a beta of -0.41.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The business had revenue of $0.01 million for the quarter. As a group, equities analysts expect that Lyell Immunopharma will post -0.78 EPS for the current fiscal year.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.